Next Article in Journal / Special Issue
Antibody Glycosylation and Inflammation
Previous Article in Journal
The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes
Previous Article in Special Issue
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Article Menu

Export Article

Open AccessReview
Antibodies 2013, 2(2), 371-391; doi:10.3390/antib2020371

Role and Redirection of IgE against Cancer

1
Molecular Immunology Group, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
2
Protein Engineering and Therapeutics Group, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
*
Author to whom correspondence should be addressed.
Received: 4 April 2013 / Revised: 13 May 2013 / Accepted: 14 May 2013 / Published: 28 May 2013
(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
View Full-Text   |   Download PDF [299 KB, uploaded 28 May 2013]   |  

Abstract

IgE is a highly elusive antibody class, yet a tremendously powerful elicitor of immune reactions. Despite huge efforts spent on the characterization and understanding of the IgE system many questions remain either unanswered or only marginally addressed. One above all relates to the role of IgE. A common doubt is based on whether IgE mode of action should only be relegated to anti-parasite immunity and allergic manifestations. In search for a hidden role of IgE, reports from several laboratories are described herein in which a natural IgE link to cancer or the experimental redirection of IgE against cancer have been investigated. Epidemiological and investigational studies are trying to elucidate a possible direct intervention of endogenous IgE against cancer, raising thus far no definitive evidence. Conversely, experimental approaches implementing several strategies and engineered IgE formats built up a series of convincing results indicating that cancer might be tackled by the effector functions of this immunoglobulin class. Because of its peculiar immune features, IgE may present a superior anti-tumor performance as compared to IgG. However, extreme care should be taken on how IgE-based anti-tumor approaches should be devised. Overall, IgE appears as a promising resource, likely destined to enrich the anti-cancer arsenal.
Keywords: IgE; FceRI; CD23; ADCC; cancer; immunotherapy IgE; FceRI; CD23; ADCC; cancer; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nigro, E.A.; Siccardi, A.G.; Vangelista, L. Role and Redirection of IgE against Cancer. Antibodies 2013, 2, 371-391.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top